5:39 PM
 | 
Jun 20, 2014
 |  BC Extra  |  Company News

Competitive bids drove Merck to double Idenix offer

The Merck & Co. Inc. (NYSE:MRK) offer for HCV company Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) more than doubled as a result of competitive bids from two other undisclosed bidders, Merck SEC filings revealed. On May 9, Merck...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >